Desferrithiocin is a new, potent, orally available iron chelator. To determine whether this drug might be useful not only for iron-overload but also for immunosuppression, we studied the in vitro effects of desferrithiocin on T-lymphocyte function. Like deferoxamine, desferrithiocin inhibited, in a dose-dependent fashion, mitogen-and lectininduced proliferation of both human and murine T cells. It was active at a concentration of 10 pg/mL. The inhibition of proliferation was reversed by ferrous chloride, but not by other metal salts, recombinant IL-2, or conditioned medium. Desferrithiocin also inhibited proliferation of constitutively dividing, and factor-independent EBV-transformed B cell and leukemic T-cell lines. Although desferrithiocin inhibited the induction of cytotoxic T lymphocyte R O N IS A N ESSENTIAL nutrient for cell growth, cell I division, and cellular differentiation. It is necessary not only for heme-containing proteins and oxidative enzymes but also for enzymes that require iron as a coenzyme. Iron chelation results in inhibition of cellular proliferation, possibly through its effect on ribonucleotide reductase, a ratelimiting nuclear enzyme essential for DNA synthesis and one that uses iron as a cofactor for activity.'.' Perhaps as a result of its effect on proliferation, iron chelation also appears to affect the immune response.
duced by Streptomycespilosus (Fig 1) . 16 The agent binds an equimolar concentration of iron to form a stable complex, ferrioxamine.I6 Deferoxamine is poorly absorbed from the gastrointestinal track and must therefore be administered parenterally, limiting patient compliance and acceptability. Recently, a new, potent, orally active iron chelator, desferrithiocin, has been developed, and shown to be considerably more effective than deferoxamine in promoting iron excretion in a simian
The sodium salt of desferrithiocin (M, 260.3), a siderophore, was generated from a product of Streptomyces antibioticus (Fig 1) . Unlike deferoxamine, it is readily absorbed from the gastrointestinal tract. In order to determine its immunosuppressive capacity, we studied the effect of desferrithiocin on T cell function in vitro. Like deferoxamine, desferrithiocin is a potent, reversible inhibitor of T-cell proliferation and mixed lymphocyte reactivity in vitro. It does not affect the expression of activation antigens on the surface of stimulated T cells, IL-2 production, or early measures of T-cell activation such as a rise in intracellular calcium ([Cai+2] ). While it inhibits the generation of cytotoxic T cells (CTL), it does not inhibit CTL-or natural killer (NK)-mediated cytotoxicity once these cells are formed. Its profound immunomodulating effects may have therapeutic applications.
MATERIALS AND METHODS
Deferoxamine B mesylate (Desferal), M, 656.8, was obtained from Ciba-Geigy (Basel, Switzerland). The sodium salt of desferrithiocin, M, 260.3, was also kindly provided by Ciba-Geigy. Both compounds were diluted into culture media immediately before use, and filter sterilized. Ferrous chloride and other metal salts were obtained from Sigma Chemical Co (St Louis, MO).
The anti-CD3 monoclonal antibody (MoAb) OKT3 (American Type Culture Collection, Rockville, MD)I9 was subcloned, and grown as ascitic fluid of pristane-primed BALB/c mice. The concentration of OKT3 MoAb used, 1:40,000 dilution of ascites fluid, induced maximal proliferation of peripheral blood mononuclear cells not depleted of accessory cells (data not shown). The MoAbs TS2/18, directed against CD2," and LB3.1, directed against monomorphic determinants of class 11 major histocompatibility complex proteins2' respectively, were used at a final concentration of 1:lOOO dilution of ascites fluid. Anti-Tac healthy volunteers was collected in preservative-free heparin (Sigma IL-2-containing human conditioned medium; or phorbol 12-myristate 13-acetate (PMA, Sigma), 10 ng/mL, plus ionomycin (Behring Diagnostics, La Jolla, CA), 0.2 pmol/L, as described below. Human conditioned medium was prepared from 72-hour culture supernatants of pooled PHA-stimulated PBMC as described in detail previo~sly.~~ The supernatants were concentrated by ammonium sulfate precipitation (50%, 75%), followed by exhaustive dialysis against phosphate-buffered saline (PBS), filter-sterilized, and stored at -2OOC. Murine splenocytes were obtained from B6AFI mice. Mice were killed by cervical dislocation, the spleen was dissected, and mononuclear cell suspensions were prepared. Cells were cultured in either anti-CD3 MoAb, 145-2C11, recognizing the e chain of the murine CD3 complex (the kind gift of Dr J. Bluestone, University of Chicago, Chicago, IL), or concanavalin A (Con A, Sigma), in the presence or absence of IL-2ontaining rat Con A supernatant, as described below.
Human PBMC were isolated, washed, plated at IO5 cells/well in triplicate in flat-bottomed 96-well microtiter plates (Costar, Cambridge, MA). Anti-CD3 MoAb, PHA, Con A, staphlococcal enterotoxin B (SEB, Sigma), PMA and ionomycin, in the presence of other reagents where indicated, were added at the start of the assay, unless otherwise stated. Cultures were incubated at 37OC with 5% CO, in a humidified atmosphere for 72 hours and labeled for the final 8 to 12 hours with 1 pCi/well [3H]-thymidine (New England Nuclear, Boston, MA), unless otherwise indicated. Cultures were harvested on a MASH I1 multiple automatic sample harvester (Microbiological Associates, Bethesda, MD). The incorporated radioactivity was measured in a Beckman liquid scintillation counter. SEM of triplicate determinations was less than 15% unless otherwise stated. PBMC from normal controls, 3 x lo5 cells/well, were cultured in 0.2 mL complete medium alone or in the presence of anti-CD3 MoAb (OKT3) in the absence or presence of an iron chelator in flat-bottom 96-well microtiter wells (Costar). Cells were cultured for 18 hours at 37OC in humidified atmosphere of 5% CO, in 95% air. In other experiments, the T-lymphoblastoid cell line Jurkat, 2 x IO5 cells/well, were cultured with media, OKT3, or OKT3 plus PMA in the presence or absence of iron chelator in duplicate in 96-well flat bottom plates (Costar) for 24 hours. Culture supernatants were collected, frozen at -8OOC to lyse residual cells, and thawed, IL-2 activity was assessed by the ability to support proliferation of an IL-Zdependent murine cell line, CTLL-20.25 CTLL-20, 5 x IO3 cells/well, was cultured with supernatants in duplicate in 96-well flat-bottom plates and proliferation was assessed by the incorporation of ['HI-thymidine during a 4-hour pulse following a 20-hour incubation. Excess concentrations of FeCl, were added at the time of CTLL-20 assay to neutralize the effect of iron chelators present in the supernatants. The amount of IL-2 present in the test supernatant was assessed by the ['HIthymidine incorporation of CTLL-20 cells relative to a standard rat Con A supernatant.
The "Cr release assay was performed in triplicate in V-bottom microtiter wells (Nunc, Roskilde, Denmark). Effector cells were counted and added in threefold dilutions in the presence or absence of iron chelator. Target cells, preincubated with 0.1 mCi of 5'Cr (Na wrO,, New England Nuclear, Boston, MA) for 2 hours, were washed three times, and added at lo' cells/well. Microtiter plates were centrifuged at 200 x g for 5 minutes and incubated for 4 hours at 37OC in 5% CO,. After incubation, the plates were again centrifuged. One hundred and twenty-five microliters of supernatant was harvested, and counted in a Packard gamma Stimulation of ZL-2 production.
Assayfor CTL activity.
For personal use only. on October 22, 2017. by guest www.bloodjournal.org From 100000 . + counter to determine 5'Cr radioactivity released. The specific lysis is calculated by the formula: %cytotoxicity = 100 [(cpm experimental release -cpm spontaneous release)/(maximum cpm release -cpm spontaneous release)].
The T-lymphoblastoid cell line Jurkat or PBMC from normal volunteers were incubated with 5 hmol/L of the acetoxymethyl ester of the calcium sensitive fluorophore Indo-1 (Molecular Probes, Junction City, OR)26 45 to 60 minutes at 37OC on a shaker platform. The Indo-1 loaded cells were washed twice, resuspended in complete medium and stored in the dark at 37OC until analysis. Cytoplasmic calcium was monitored by flow cytometry using an Epics V Coulter as described." The ratio of fluorescence emissions, 405 nm/480 nm, reflects the relative [Ca2'], and is plotted on the X-axis, cell number on the Y-axis, as a function of time on the Z-axis. The resting relative [Ca2+], was measured and is displayed as the first 30 seconds of each panel, after which antLCD3 MoAb, 1:lOOO dilution of ascites fluid, was added. Responses were monitored for 7 minutes. Temperature was maintained at 37OC.
Determinafion of[Ca"],.

RESULTS
Like deferoxamine. desferrithiocin inhibits T-cell proliferation.
Human PBMC were incubated with the mitogenic anti-CD3 MoAb OKT3 and various concentrations of either deferoxamine or desferrithiocin (Fig 2A) . Both ironchelating agents caused a marked and dose-dependent inhibition of proliferation as measured by the incorporation of [3H]-thymidine. Concentrations of 10 pg/mL of either agent completely suppressed T-cell proliferation.
Like deferoxamine, desferrithiocin inhibited proliferation stimulated not only by anti-CD3 MoAb, but also by the mitogens PHA and Con A (data not shown) and by the toxin staphlococcal enterotoxin B (SEB) (Fig 2B) . Similarly, stimulation of PBMC proliferation by the combination of PMA and ionomycin, which together bypass the requirement for receptor expression a t the cell surface, was also inhibited by the addition of either deferoxamine or desferrithiocin ( Fig  2C) . The concentration of each iron chelator required to inhibit cell proliferation was similar regardless of the mitogenic stimulus.
The anti-proliferative effects of desferrithiocin and deferoxamine were not species-specific. Murine spleen cells were isolated by density gradient centrifugation and stimulated with either Con A or the anti-CD3 MoAb 145-2C11 in the presence or absence of rat Con A-stimulated supernatant (RCM) as a source of exogenous growth factors. Both desferrithiocin and deferoxamine inhibited the proliferation of murine spleen cells as effectively as that of human resting peripheral blood leukocytes (data not shown).
Desferrithiocin-induced inhibition of proliferation is reversed by iron. To ensure that the iron-chelating ability of desferrithiocin was responsible for the inhibition of PBMC proliferation, human cells were incubated with anti-CD3 MoAb, desferrithiocin or deferoxamine at varying concentrations, and excess concentrations of ferrous chloride (Fig 3) . The addition of ferrous chloride completely reversed the inhibition of proliferation induced by either desferrithiocin (Fig 3A) or deferoxamine (Fig 3B) at all concentrations except 100 pg/mL, a t which concentration modest inhibition of proliferation persisted. It appeared that these compounds were toxic to the cells a t the 100 pg/mL concentration. For future studies, a concentration of 10 pg/mL deferoxamine or desferrithiocin was chosen. The addition of ferrous chloride to cultures stimulated not only with anti-CD3 MoAb but also with PHA, PMA plus ionomycin or SEB effectively reversed the inhibition of proliferation observed with desferrithiocin or deferoxamine (data not shown). In contrast, the addition of other metal salts, including MgCl,, ZnSO,, CuSO,, or CaCI, failed to restore proliferation in desferrithiocin or deferoxaminetreated cultures, a t concentrations that had little or no direct inhibitory effect to the cultures (data not shown).
Mitogen-induced stimulation of proliferation was measured a t 72 hours after initiation of culture. Inhibition of anti-CD3 MoAb-induced proliferation by the iron chelators could be reversed if ferrous chloride was added as late as 24 hours after the addition of anti-CD3 MoAb (Fig 4) . Therefore, the iron chelators were not directly toxic to the cells, and proliferation could be restored after long exposure to either agent. In addition, PBMC pretreated with either desferrithiocin or deferoxamine for two hours, washed, and then stimulated with either anti-CD3 MoAb or PHA were able to proliferate comparably to control cultures, suggesting that the effects of the agents were fully reversible (data not shown). Jurkat cells were preincubated for two hours with either desferrithiocin or deferoxamine, each at 10 pg/mL, and then loaded with the calcium sensitive fluorophore Indo-1 AM. The relative [Ca+'], was measured by the ratio of fluorescence emission at 405 nm (Ca+'-bound) to 480 nm (Ca+'-free) using flow cytometric analysis and was plotted versus time. Despite 2-hour preincubation, the addition of either agent failed to inhibit an early rise in [Ca+'], induced by triggering the TcR-CD3 complex with anti-CD3 MoAb ( Fig  5) . Similarly, neither desferrithiocin (10 pg/mL) nor deferoxamine (10 pg/mL) inhibited the characteristic rise of [Ca+'Ii stimulated by PHA in freshly isolated PBMC despite complete inhibition of mitogen-induced proliferation at this concentration (data not shown).
It has been previously shown that the T-cell stimulation is associated with the expression of activation antigens, including the IL-2 receptor. The expression of cell surface activation antigens on PBMC cultured in the presence of PHA in the presence or absence of desferrithiocin and deferoxamine was determined. The addition of either agent did not affect the induction of IL-2 receptor (CD25) expression by PBMC cultured for 3 days with PHA (Fig 6) . Similarly, neither the mean fluorescence intensity nor the percentage of positively staining cells for CD25, HLA-DR, CD3, or CD2 was significantly affected by culture with either desferrithiocin or deferoxamine (data not shown).
The production of ZL-2 is not affected by desferrithiocin or deferoxamine. The production of IL-2 by PHAstimulated PBMC may be assessed by determining the ability of stimulated culture supernatants to support the growth of an IL-2 dependent cell line CTLL-20. 25 To this to IL-2 also failed to restore proliferation, suggesting that a deficiency of another required growth factor besides IL-2 was not likely to be responsible for the inhibition of proliferation (data not shown). Taken together, these data suggest that neither desferrithiocin nor deferoxamine inhibit early measures of transmembrane signaling such as a rise in [Caf2], or later events such as IL-2 receptor expression and IL-2 production. biologic assay, excess FeCl, was added to neutralize the effect of the iron chelators on the proliferation of CTLL-20. There was no significant difference between the IL-2 content of PHA-stimulated cultures in the absence (1 12 U/mL) or presence of either 10 Mg/mL desferrithiocin (125 U/mL) or 10 pg/mL deferoxamine (134 U/mL). The addition of exogenous recombinant IL-2 to mitogen-stimulated PBMC did not restore proliferation inhibited by either desferrithiocin or deferoxamine (Table 1) . Furthermore, the addition of human conditioned medium containing cytokines in addition Given that these early events in T-cell activation did not appear to be influenced by iron chelation, we sought to determine how long after initiation of culture inhibition of proliferation by desferrithiocin or deferoxamine could be demonstrated. PBMC werestimulated with anti-CD3 MoAb, and desferrithiocin or deferoxamine was subsequently added at later, varying time intervals. All cultures were pulsed with [3H]-thymidine at 72 hours and harvested 8 hours later. Greater than 50% suppression of proliferation was observed if either agent was added up to 50 hours after initiation of the
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Log Fluorescence Intensity - PBMC were cultured in medium or anti-CD3 MoAb, OKT3 1:40,000 dilution of ascites fluid, PHA 2 pg/mL, or PMA 10 ng/mL plus ionomycin 0.5 pmol/L in the absence or presence of desferrithiocin, 10 pg/mL, or deferoxamine, 10 pg/mL. Cultures were harvested at 72 hours after a 9-hour pulse with [3H]-thymidine as described in Materials and Methods.
proliferative stimulus (Fig 7) . No significant effect was observed if either agent was added a t 60 hours or later. The data demonstrate that iron chelation can inhibit an ongoing proliferative response.
Like deferoxamine. desferrithiocin inhibited mixed lymphocyte reactivity. Because mixed lymphocyte reactivity depends on proliferation, we wished to determine whether this reactivity was also affected by the presence of iron chelation. Freshly isolated PBMC were stimulated with irradiated allogeneic stimulator cells, and harvested for proliferation on day 6. Both desferrithiocin and deferoxamine markedly suppressed DNA synthesis, a n inhibition that was reversed by the addition of ferrous chloride (data not shown).
The effect of desferrithiocin on cell-mediated cytotoxicity was tested. Cells were stimulated by the stimulator cell line, JY, an Epstein-Barr virus-transformed human B-cell line. At six days, there was no generation of cytolytic T-cell ability in the presence of either desferrithiocin, 33 pg/mL, or deferoxamine, 33 pg/mL (Fig 8) . Thus, iron chelation inhibited the development of a mixed lymphocyte response and of CTL effector cells.
Iron chelation did not inhibit CTL or NK-mediated cytotoxicity. Because iron chelation inhibited the generation of CTL activity from naive T cells, we tested whether desferrithiocin inhibited cytotoxicity of preformed CTL. The ability of a long-term CTL line to kill its target cell was not inhibited by the addition of the iron chelator (Table 2) . Similarly, freshly isolated PBMC were able to kill the natural killer (NK)-sensitive erythroblastoid cell line K562 in the presence of the iron chelator (Table 2) . Therefore, neither desferrithiocin (Table 2) nor deferoxamine (not shown) inhibited CTL-or NK-mediated cytotoxicity.
Iron chelation inhibits proliferation of spontaneously dividing, and factor-independent cell lines. To confirm that the inhibition of proliferation was not secondary to any exogenous factor required for DNA synthesis besides iron, we tested the ability of desferrithiocin and of deferoxamine to inhibit proliferation of spontaneously dividing cells. The T-lymphoblastoid cell line Jurkat, the EBV-transformed cell Cytolytic activity is expressed as percent specific 51Cr release in four hours as described in Materials and Methods. NK effector cells, freshly isolated PBMC, were used at a ratio of 33: 1 against "Cr-labeled K562 cells. The CTL effector cell line was used at a ratio of 6:l against "Cr-labeled JY cells.
For personal use only. on October 22, 2017 . by guest www.bloodjournal.org From line JY, and the erythroleukemia cell line K562 were each cultured in the absence or presence of the iron-chelating agents. Like deferoxamine, desferrithiocin inhibited, in a dose-dependent fashion, the proliferation of constitutively dividing, and factor-independent cell lines (data not shown).
DISCUSSION
In this report, we have shown that the oral agent desferrithiocin, like deferoxamine, inhibited, in a dose-dependent fashion, mitogen-and lectin-induced proliferation of both human and murine T cells. The inhibition was reversed by ferrous chloride, but not by other metal salts, recombinant IL-2, or human conditioned medium. Desferrithiocin also inhibited proliferation of spontaneously dividing, and factorindependent, EBV-transformed B-cell and leukemic T-cell lines. Similar concentrations of iron chelator was required to inhibit proliferation of PBMC and transformed B-and T-cell lines. While the iron chelators inhibited both the generation of a mixed lymphocyte response and the induction of CTL activity, they did not inhibit CTL-or NK-induced cytotoxicity. The agents did not inhibit the expression of activation antigens, such as the IL-2 receptor, transferrin receptor, or HLA-DR on T cells, or early measures of T-cell activation such as influx of [Ca+*],. The effect of iron chelation was nontoxic and reversible; saturating concentrations of iron could reverse the inhibition of proliferation if added as late as 24 hours after initiation of culture. Thus, desferrithiocin, like deferoxamine, is a potent and reversible inhibitor of T-cell proliferation. This anti-proliferative effect inhibits T-cell differentiation and CTL formation, but T-cell functions such as IL-2 production and the function of preformed cytotoxic cells are preserved.
The studies reported here extend previous reports of the effect of iron chelation on T-cell function in vitro. Iron chelators inhibit proliferation and differentiation of naive T cells, but do not inhibit either lymphokine release or CTL-or NK-mediated killing of preformed or mature T cells. Thus, iron chelation does not eliminate the T-cell response, but rather limits the development of and recruitment of new alloreactive or autoreactive T cells. Previous studies have shown that deferoxamine inhibits DNA synthesis, PBMC proliferation, and the MLR.'6*32-34 Our data are consistent with those previously reported, which indicate that the agent acts, at least in part, as an inhibitor of ribonucleotide reductase; the latter uses iron as a coenzyme and is essential for DNA synthesi~.~.~ Our data do not distinguish between inhibition of cell cycle progression from Go to and a block in early S phase. 33 The addition of deferoxamine, 10 pg/mL or 15 pmol/L, (and of desferrithiocin) to PHA-stimulated PBMC did not inhibit IL-2 production or IL-2 receptor expression. This latter observation is in disagreement with that reported for the effect of deferoxamine on PHA-stimulated PBMC by Lederman et These authors used deferoxamine at a concentration of 250 pg/mL or 360 pmol/L, a concentration that, in our hands, appears to be toxic to the cells.
Somewhat higher concentrations (33 pg/mL) of either desferrithiocin or deferoxamine were required to completely inhibit the generation of CTL-mediated cytotoxicity than to inhibit T-cell proliferation (10 pg/mL). Whether this relates to residual natural killer (NK) activity, which is not inhibitable by desferrithiocin or deferoxamine (Table 2) , in the culture remains to be determined.
Desferrithiocin appears to be effective a t a concentration of 10 pg/mL, or 38 pmol/L, while deferoxamine is effective at the same concentration, 10 pg/mL, or 15 pmol/L. Deferoxamine is able to bind an equimolar concentration of iron to yield the stable complex ferrioxamine. Two molecules of desferrithiocin are, however, required to bind one molecule of iron.'833s Therefore, the molar concentration of desferrithiocin required to bind one mole of iron is twice that of deferoxamine. This explains the apparent discrepancy between the molar efficacy of the two compounds.
The immunomodulating properties of deferoxamine have been exploited in vivo to inhibit graft rejection and autoreactive T cells. Using a model of murine pancreated allografts, deferoxamine administration appeared to reduce chronic islet cell reje~ti0n.I~ The administration of continuous deferoxamine reduced the severity and duration of experimental allergic encephalomeyelitis in rats, a cell-mediated autoimmune demyelinating disease.13 Delayed type hypersensitivity was diminished and T-cell number was reduced in the tissue lesions, suggesting that the immunosuppressive properties of the agent might be responsible for the attenuation of the disease. Administration of deferoxamine has been used to treat graft-versus-host disease in human bone marrow transplant allograft recipient^.'^ Furthermore, deferoxamine has been used to treat a patient with refractory acute leukemia, demonstrating its antiproliferative effect on dividing cells.36 In this patient, the suppression of blast colony growth in vitro and treatment in vivo were accompanied by differentiation from lymphoid to myelomonocytic surface antigen e x p r e~s i o n .~~ Bioavailability after oral administration is a unique property of desferrithiocin. Oral delivery would make desferrithiocin an attractive alternative to deferoxamine as an immunosuppressant and, possibly, as a cytoreductive agent.
In an iron-loaded Cebus monkey model, desferrithiocin was found to have significant activity as an oral chelator.".'* But chronic administration of this powerful chelator desferrithiocin to non-iron-overloaded mice and rats is known to be toxic perhaps because essential iron stores are compromised." Careful study of dose and of schedule will be required if this orally active chelator desferrithiocin is to emerge as potential therapy not only for iron-overload but also for a variety of inflammatory conditions. For personal use only. on October 22, 2017 . by guest www.bloodjournal.org From
